OSAKA – Hitachi Ltd. and Kyoto University’s iPS cell research institute will launch a project to compare induced pluripotent stem cells generated from patients with diseases and from healthy volunteers to help develop new drugs and learn more about disease mechanisms.
The project, expected to start later this month, will utilize iPS cells to replicate symptoms of illness and genetic mutation outside patients’ bodies, officials said Monday.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.